Last updated: February 16, 2026
What is NDC 00456-1120?
NDC 00456-1120 is the National Drug Code for Eliquis (apixaban), an oral anticoagulant developed by Bristol-Myers Squibb and Pfizer. Approved by the FDA in 2012, Eliquis is marketed primarily for stroke prevention in non-valvular atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE). Its mechanism involves direct factor Xa inhibition.
Market Overview
The global anticoagulant market is projected to reach approximately USD 20 billion by 2027, growing at a compound annual growth rate (CAGR) of 6-8% from 2023.[1] Eliquis's market share within direct oral anticoagulants (DOACs) remains substantial, competing closely with rivaroxaban (Xarelto) and dabigatran (Pradaxa).
Market Size and Growth Drivers
- Historical Sales Data: Eliquis achieved USD 8 billion in worldwide sales in 2022, representing over 25% of the global NOAC (novel oral anticoagulants) market.[2]
- Key Drivers:
- Increasing prevalence of atrial fibrillation, DVT, and PE.
- Adoption over warfarin due to fewer food/drug interactions.
- Growing awareness and diagnosis rates.
- Expansion into additional indications, including prophylaxis in orthopedic surgeries.
Competitive Landscape
| Brand |
Indications |
Market Share (2022) |
Key Differentiators |
| Eliquis |
AFib, DVT, PE, orthopedic prophylaxis |
45% |
Superior bleeding profile |
| Xarelto |
same indications |
40% |
Once-daily dosing |
| Pradaxa |
AFib, DVT, PE |
10% |
Extensive clinical history |
| Others |
Various |
5% |
Niche uses, emerging competitors |
Pricing Dynamics
Current Price Points
- USA: The average wholesale price (AWP) for Eliquis 5 mg, 60-count bottle, is approximately USD 480–500, equating to about USD 8.33 per tablet.
- International: Pricing varies; European markets often see reduced costs due to negotiation and reimbursement policies.
Price Trends
- The retail price has remained relatively stable over the past three years.
- Despite patent exclusivity until at least 2030 (pending potential patent challenges), generic competition is minimal in the US due to patent integrity and legal enforcement.
Patent and Regulatory Landscape
- First patent filed in 2007; patents extend through 2030.[3]
- Patent litigations and challenges, such as Abbreviated New Drug Application (ANDA) filings, are active but have so far not resulted in significant generic market entry.
- FDA approved multiple biosimilars, but none are directly applicable to Eliquis.
Forecasting Price Trajectory
| Timeline |
Price Prediction |
Rationale |
| 2023–2025 |
Stable with potential minor discounts for bulk |
Patent protection remains strong; minimal generic threat |
| 2026–2030 |
Slight decline anticipated due to patent expiration |
Patent expiration slowly approaches; generic entry unlikely until 2030 |
| Post-2030 |
Potential 20-40% decline with generic competition |
Market saturation increases; pricing pressure intensifies |
Assumption: Patent robustness persists until 2030, delaying significant price erosion.
Risks and Opportunities
-
Risks:
- Patent litigation undermining exclusivity.
- Regulatory hurdles delaying biosimilar approvals.
- Competitive entry from emerging anticoagulants, such as factor Xa inhibitors with different mechanisms.
-
Opportunities:
- Expanding indications can sustain demand.
- Price discounts negotiated with payers could boost volume.
- Potential for combination therapies or novel formulations.
Key Takeaways
- Eliquis (NDC 00456-1120) holds a significant market position among DOACs with stable pricing until patent expiry.
- The US average price per tablet has remained steady; no significant discounts are forecasted before patent expiration in 2030.
- Market growth is driven by expanding indications and increasing prevalence of target conditions.
- Price declines are expected post-2030 with the entry of generics and biosimilars.
- Competitive landscape and patent litigation remain key uncertainties.
FAQs
1. What factors could accelerate price declines for Eliquis?
Patent litigation or successful challenges to exclusivity, regulatory approvals of biosimilars or generics, and increased competition from other oral anticoagulants could accelerate pricing reductions.
2. Are biosimilars relevant for Eliquis?
No. Eliquis is a small molecule anticoagulant, so biosimilars do not apply; generic small-molecule versions are more pertinent.
3. How might expanded indications impact Eliquis revenue?
While expanding approved uses can increase demand, they generally do not alter price unless tied to new formulations or delivery methods that justify premiums.
4. What are the main price points to watch in the future?
The USD 8.33 per tablet mark in the US remains stable until patent expiration, after which prices could decline by up to 40% within a few years of market entry by generics.
5. Are there geographic differences in pricing?
Yes. US prices tend to be higher due to limited negotiation leverage, while European and other markets often see lower prices due to national health system negotiations.
Sources
[1] Grand View Research, "Anticoagulant Drugs Market Size & Trends," 2023.
[2] Bristol-Myers Squibb, "Eliquis Global Sales Data," 2022.
[3] FDA Patent Database, "Eliquis Patent Timeline," 2023.
